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Abstract
Background: The surfactant proteins B (SP-B) and C (SP-C) are important for the stability and
function of the alveolar surfactant film. Their involvement and down-regulation in inflammatory
processes has recently been proposed, but their level during neutrophilic human airway diseases
are not yet known.
Methods: We used 1D-electrophoresis and Western blotting to determine the concentrations
and molecular forms of SP-B and SP-C in bronchoalveolar lavage (BAL) fluid of children with
different inflammatory airway diseases. 21 children with cystic fibrosis, 15 with chronic bronchitis
and 14 with pneumonia were included and compared to 14 healthy control children.
Results: SP-B was detected in BAL of all 64 patients, whereas SP-C was found in BAL of all but 3
children; those three BAL fluids had more than 80% neutrophils, and in two patients, who were re-
lavaged later, SP-C was then present and the neutrophil count was lower. SP-B was mainly present
as a dimer, SP-C as a monomer. For both qualitative and quantitative measures of SP-C and SP-B,
no significant differences were observed between the four evaluated patient groups.
Conclusion: Concentration or molecular form of SP-B and SP-C is not altered in BAL of children
with different acute and chronic inflammatory lung diseases. We conclude that there is no down-
regulation of SP-B and SP-C at the protein level in inflammatory processes of neutrophilic airway
disease.
Background
With each litre of air people inhale, the lung is exposed on
average to at least one microorganism, in conjunction
with particulates, antigens and possibly noxious gases [1].
In the lower lung, a thin film of surfactant in the epithelial
lining fluid of the airspaces, represents the first line of
defence to this burden of airborne pathogens and toxins.
Pulmonary surfactant is a highly surface-active, complex
mixture of approximately 90% lipid and 10% proteins
[2,3]. Whereas the role of the surfactant proteins B (SP-B)
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and C (SP-C) as the critical surface tension lowering pro-
tein components of lung surfactant [4] are well estab-
lished, their role in innate immunity is not yet.
SP-B is synthesized by alveolar type II cells to the mature
8 kDa protein and secreted into the alveolar space, where
it is mainly found as a dimer [5]. Bronchoalveolar Clara
cells also express pro-SP-B, but do not process it to the
mature form. Instead, a 24 kDa proSP-B form is secreted
into the alveolar space.
The main functions of SP-B are to increase the adsorption
rate of phospholipids at the air-water interface and an
involvement in the formation of tubular myelin together
with SP-A and calcium [2,6]. Apart from that, anti-inflam-
matory properties as well as protection from oxygen-
induced lung injuries have been described for SP-B [7,8].
SP-B has direct antibacterial activities; however this is
inhibited by surfactant phospholipids and not selective to
bacteria as also red blood cells are lysed, suggesting that
endogenous SP-B may not play a significant role in alveo-
lar host defense [9].
There are some data available on the levels of SP-B in the
alveolar space, but almost no data on the molecular
organization of SP-B and of pro-SP-B during various dis-
ease states [10]. Children and adults with bacterial pneu-
monia had unchanged levels of SP-B in their lavages
[11,12]. Similarly, SP-B was unchanged in young and in
adult patients with cystic fibrosis [13,14]. Infants with
cystic fibrosis (CF) had the same SP-B concentrations in
bronchoalveolar lavage fluid with or without active pul-
monary infection or inflammation as controls [15]. SP-B
content in lavage remained unchanged in Pneumocystis-
pneumonia, but decreased significantly in ARDS and
other forms of pneumonia [16]. SP-B was low in the BAL
of patients at risk for ARDS before the onset of clinically
defined lung injury, and in patients with established
ARDS [17]. SP-B was lower in infants ventilated for severe
RSV infection compared to healthy controls, ventilated
post-surgery [18].
SP-C is exclusively synthesized by alveolar type II pneu-
mocytes and secreted into the alveolar space [19]. It stabi-
lises the alveolar surfactant film by enhancing the
adsorption rate of phospholipids [20,21] and by increas-
ing the resistance of surfactant against inhibition by
serum proteins or oedema fluid [2]. In addition to these
functions related to surface tension, SP-C may also be
involved in host defense.
SP-C inserted into lipid vesicles interacts with a 12 residue
non-transmembrane domaine with bacterial lipopolysac-
charide; this enhances the association and the binding
efficacy between lipopolysaccharide and CD14, a receptor
on phagocytes [22,23].
Recently in various animal models of lung injury the reg-
ulation of SP-C expression by inflammation has been
highlighted. SP-C concentrations were reduced in bleo-
mycin induced lung fibrosis, hyperoxia, Aspergillus fumi-
gatus and Pneumocystis jiroveci infections and a model of
asthma, suggesting down-regulation of SP-C expression
by pulmonary infection and inflammation. Unfortu-
nately, there are not many ex vivo data available on the
concentration and the molecular organization of SP-C in
bronchoalveolar lavage of humans.
In adults, SP-C content in large aggregate surfactant
remained unchanged in pneumocystis pneumonia, but
decreased significantly in ARDS and other pneumonia
[16]. Children and young adults with cystic fibrosis had
increased SP-C [13,14]. Similarly, children with malig-
nancies and immunosuppression during fever and pul-
monary infiltrates, had two-fold increased levels of SP-C
[24]. The available data contradict or only in part support
the notion of a down-regulation of SP-C during pulmo-
nary infection and inflammation.
The major goal of this study is therefore to investigate the
concentrations and molecular forms of SP-B and SP-C and
their pro-forms in the alveolar space under different infec-
tious and inflammatory disease conditions.
Methods
Patients
Bronchoalveolar lavage fluid (BALF) from children and
young adults with different chronic and acute inflamma-
tory airway diseases including cystic fibrosis (CF), chronic
bronchitis, acute pneumonia and a comparison group of
subjects without lung disease (controls) was investigated.
CF was diagnosed by repeated sweat tests with elevated
chloride concentrations together with the characteristic
clinical presentation. 14 of 21 children were deltaF508
homozygous and 4 heterozygous. In 3 patients no muta-
tion was detected by routine screen for the 30 most prev-
alent mutations in Germany. All patients were clinically
stable, none had evidence for allergic bronchopulmonary
aspergillosis or advanced hepatic disease. Some children
with CF were part of the "bronchoalveolar lavage for the
evaluation of anti-inflammatory treatment" (BEAT) study,
a multicenter study to evaluate the effect of treatment with
rhDNase on endobronchial inflammation, and were
recruited in the Berlin and Munich centres [25]. Others
underwent BAL for diagnostic purposes. Within the group
of evaluated CF-patients no significant changes in the sur-
factant proteins and their quantitative appearance wasBMC Pulmonary Medicine 2008, 8:6 http://www.biomedcentral.com/1471-2466/8/6
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observed between patients treated or not treated with
rhDNase.
The 15 children in the chronic bronchitis group suffered
from bronchitis without obstruction over a period of at
least 3 months and endobronchial inflammation was
diagnosed visually by bronchoscopy. Cystic fibrosis, pri-
mary ciliary dyskinesia, cellular or humoral immune defi-
ciencies, gastro-oesophageal reflux disease and anatomic
anomalies of the airways were excluded if clinically indi-
cated. None of them had a pulmonary infiltrate in the x-
ray or were diagnosed as having bronchial asthma
(obstructive bronchitis).
Inclusion criteria for the 14 children in the pneumonia
group were clinical symptoms (cough and/or fever) and a
pulmonary infiltrate in x-ray and/or computer tomogra-
phy. Exclusion criteria were interstitial pneumonia,
immune deficiencies and malignancies as a reason for the
pneumonia.
The 14 children of the control group did not have any ill-
ness with pulmonary affection. Here BAL was performed
during anesthesia for elective surgery for minor condi-
tions (excision of haemangioma, tonsillectomy, circumci-
sion, hand surgery or groin hernia).
Clinical details of the children, the cellular results, total
protein content and the microbiology results of the bron-
choalveolar lavage are given in Table 1.
The study was approved by the ethics committee at the
University of Munich. Written informed consent was
obtained from the parents and/or the patients with appro-
priate age.
Bronchoalveolar Lavage Procedure
BAL was performed using a 3.5 mm or 4.9 mm flexible
bronchoscope in "wedge position" in a subsegment of the
right middle lobe or the lingula. 4 × 1 ml/kg body weight
saline (0.9%) at body temperature was instilled and
immediately withdrawn by suction. The first aliquot of
the recovered lavage fluid was treated separately. Fractions
2–4 were pooled and cleaned by gauze-filtration. The total
cell count was measured by a haemocytometer and the
differential cell count of the BALF by cytocentrifugation.
The supernatant was used for the following analysis of
total protein content and surfactant proteins.
Surfactant Protein Analysis
Total protein content was determined according to the
method of Bradford 1976 [26] with the BioRad Protein
Assay Kid (BioRad, Richmond, CA, USA). For each patient
four BALF samples containing 5 µg total protein each were
prepared to detect (Pro-)SP-B and (Pro-)SP-C under
reducing and SP-B and SP-C under non reducing condi-
tions. The proteins were separated on NuPage 10% Bis-
Tris gels using a Novex X-cell II Mini Cell system (Novex,
San Diego, CA, USA) and then transferred onto nitrocellu-
lose membranes by Western Blot in Nupage Blot modules
(Novex, San Diego, CA, USA). Membranes with protein
separated under reducing conditions were first incubated
with pro-SP-B-antibody (recombinant anti-human from
rabbit, C-terminal, charge 1/24/00, from Guttentag, USA)
respectively SP-C-antibody (recombinant anti-human
from rabbit, charge 22/96, from Byk-Gulden, Konstanz,
Germany) and then with SP-B-antibody (recombinant
anti-human from rabbit, charge C 329, from Byk-Gulden,
Konstanz, Germany) respectively antibody against pro-
SP-C (recombinant anti-human from rabbit, N-terminal,
from Beers, USA). As second antibody we used peroxidase
conjugated goat Ig-G anti rabbit from DIANOVA, Ham-
burg, Germany. The membranes were activated with
enhanced chemiluminescence assay before exposing
them to x-ray films (Hyperfilm ECL, Amersham Bio-
sciences, Buckinghamshire, UK). After development the
films were scanned with the FluorS Multi-Imager and the
bands were analysed using the software-program "Quan-
tity One". Apart from the qualitative evaluation a quanti-
tative analysis was performed by multiplication of the
optical density and the average diameter of each band.
The comparison with standard curves (Figure 1) allowed
Table 1: Patients characteristic and bronchoalveolar lavage cells, protein content and bacteria
Cystic fibrosis Chronic bronchitis Pneumonia Healthy controls
n (male) 21 (10) 15 (5) 14 (9) 14 (9)
Age (years) 14.0 (11.7 – 17.3) 4.2 (0.8 – 7.2) 2.1 (0.9 – 4.9) 7.6 (2.2 – 23.3)
FEV1 (% pred) 89.0 (79.1 – 97.7) 100.0 (100.0 – 108.0) 96.0+ n.d.
Total cells (× 106/ml) 7.3 (0.8 – 31.9) 14.5 (10.5 – 26.0) 20.5 (9.5 – 50.8) 9.2 (6.6 – 16.1)
PMN (%) 40.6 (2.2 – 79.8) 2.0 (1.0 – 7.0) 13.0 (2.5 – 56.0) 1.1 (0.8 – 2.0)
Total protein (µg/ml) 81.0 (51.4 – 130.2) 103.1 (85.8 – 166.1) 120.0 (88.6 – 159.5) 68.5 (51.7 – 87.9)
P. aeruginosa (x/n) 8/21 0/15, other 5/15 1/14, other 10/14 0/14
St. aureus (x/n) 7/21 0/15, other 5/15 1/14, other 10/14 0/14
Data are median and 25./75. percentile; n.d. not done; other (2 Pseudomonas, 2 Klebsiella, 1 Staphylococcus, 4 Pneumococcus, 6 Haemophilus, 1 E. 
coli (16 different bacteria, one patient had two different strains isolated); + Only one patient with pneumonia was assessed by lung function.BMC Pulmonary Medicine 2008, 8:6 http://www.biomedcentral.com/1471-2466/8/6
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(UPPER PANEL) Representative Western blots of SP-B, SP-C and their proforms Figure 1
(UPPER PANEL) Representative Western blots of SP-B, SP-C and their proforms. Specific bands are marked with 
arrows. The frequency at which bands were detected at the respective molecular weights is listed in Table 2. Some blots also 
showed additional bands which were the residuals from previous incubations of the same blots with the other antibody (pro-
SP-C was detected after the blot was incubated with SP-C, and SP-B after Pro-SP-B). In none of the patients pro-SP-C was 
detected. The arrow indicates the positive control for pro-SP-C in a lavage of a patient with a SP-C mutation and the presence 
of pro-SP-C in his lavage. (MIDDLE PANEL) Initially in samples CF-20-1 and CF-21-1, no SP-C was detected. Addi-
tional BALF samples from the same patients at later time points were available and run in addition. SP-C was only detected in 
samples CF 20-2 and CF 21-2. (LOWER PANEL) Interestingly samples CF 20-1 and CF 21-1 showed a clear posi-
tive reaction with the pro-SP-C-antibody at a molecular weight of 3 – 4 kDa. This might be fragments of pro-SP-C 
which reacted to the antibody or non-specific bands (arrow). All other bands in blot C) were non specific (#). * band from pre-
vious incubation # non-specific reaction.BMC Pulmonary Medicine 2008, 8:6 http://www.biomedcentral.com/1471-2466/8/6
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approximate determinations of the amount of SP-B and
SP-C in each patient sample.
Statistical Analysis
Statistical analysis was performed with Graph Pad Prism
Version 4.01 (San Diego, CA, USA) and Microsoft Excel
2000 (San Francisco, CA, USA), using Kruskal Wallis
Anova for non-parametric results (given as median and
25. and 75. percentile) or Fisher's exact test for frequency
distributions, corrected according to Bonferroni for multi-
ple comparisons. Correlation coefficients were deter-
mined according to Spearman. A p-value of less than 0.05
was considered as being significant.
Results
Surfactant protein B (SP-B)
All 64 patients had SP-B in their lavages (Table 2). SP-B
was uniformly present as a dimer, about half of the sub-
jects also had monomers and few aggregates with the
molecular weight of four SP-B molecules. Under reducing
conditions, only monomers at about 8 kDa were present
(Fig. 1A, Table 2). No differences between the four groups
of subjects were found (Table 2).
The major physiologic form of pro-SP-B with a molecular
weight of 24–25 kDa was found in the lavages of all 21
patients with CF, 14 of 15 children with chronic bronchi-
tis, 12 of 14 patients with pneumonia and 13 of 14 chil-
dren and young adults from the control group (overall in
94%) (Fig. 1A).
The level of SP-B was not associated with the degree of
neutrophilic inflammation or the presence or absence of
bacteria in BALF (Fig. 2, Fig. 3).
Quantitatively there were no significant differences
between the four groups of patients investigated (Fig. 3).
Because of shortage of BAL fluid in the healthy controls,
only 4 patients were analysed under non-reducing condi-
tions, and the results under reducing conditions were
given in addition.
Surfactant protein C
61 of 64 patients had SP-C in their lavages (Table 2). In
the samples CF 20-1 and CF 21-1 of the patients CF 20
and CF 21 (CF-group) and the patient P 14 (pneumonia-
group) SP-C could not be detected. With 92% (CF 20-1),
93.1% (CF 21-1) and 80% (P 14) neutrophil granulocytes
in BALF, these patients had the highest levels of pulmo-
nary inflammation of their groups at the time of the lav-
age. In contrast, in the BALF-samples CF 20-2 and CF 21-
2, which were taken from the patients CF 20 and CF 21 at
a time were they had a lower level of pulmonary inflam-
mation (57% and 43% neutrophiles), SP-C was regularly
detected (Fig. 1B).
Pro-forms of SP-C were not found in any of the analysed
samples. Only the Western blots of the samples CF 20-1
and CF 21-1 showed a reaction with the pro-SP-C-anti-
body at a molecular weight between 3 and 4 kDa; this was
not observed in the blots of the samples CF 20-2 and CF
21-2, taken later (Fig. 1C). It is likely that this represents
proteolytically degraded pro-SP-C, consisting of pro-SP-C
peptide reactive with pro-SP-C antibody.
Between the four evaluated groups no significant differ-
ences were found in the quantity of SP-B and SP-C (Fig.
4). When comparing the quantitative results of SP-C from
samples analysed under reducing with those analysed
under non-reducing conditions, slightly higher amounts
of protein were detected under non-reducing conditions
(not shown). This could either indicate that the used anti-
bodies were less sensitive for the detection of SP-C in
reduced forms, or that protein was destroyed during the
reducing process. Similarly as described before for SP-B,
because of shortage of BAL fluid in the healthy controls,
only 4 patients were analysed under reducing conditions
(Fig. 4).
Similarly as for SP-B, SP-C concentration in BALF was not
related to the degree of neutrophilic inflammation or the
presence or absence of bacteria in BALF (Fig. 2, Fig. 3). For
both SP-B and SP-C, no age-dependencies were observed.
Table 2: Frequency of detection of SP-B, SP-C and their proforms in bronchalveolar lavages at the indicated molecular weights 
determined by Western blotting
SP-B Pro-SP-B SP-C Pro-SP-C
Western blot bands at (kDa) 8 16–18 30 19–21 24–25 4.2 7 3–4 15–16
CF (n = 21) 14 (67) 21 (100) 16 (76) 4 (19) 21 (100) 19 (90) 5 (26) 2 (10) 0 (0)
Chronic bronchitis (n = 15) 9 (60) 15 (100) 9 (60) 2 (13) 14 (93) 15 (100) 4 (26) 0 (0) 0 (0)
Pneumonia (n = 14) 4 (29) 14 (100) 6 (43) 1 (7) 12 (86) 13 (100) 2 (14) 0 (0) 0 (0)
Healthy controls (n = 14 for SP-B (not shown) and pro-SP-B 
reduced, n = 4 for SP-B non-reduced)
1 (25) 4 (100) 2 (50) 2 (14) 13 (93) 14 (100) 3 (21) 0 (0) 0 (0)
Absolute rate of detection, in brackets %. Western blots for SP-B and SP-C under non-reducing conditions, for pro-SP-Band pro-SP-C under 
reducing condition. Frequencies were compared by Fisher's exact test and corrected for the comparisons made within each group of molecular 
weights. No significant differences were detected.BMC Pulmonary Medicine 2008, 8:6 http://www.biomedcentral.com/1471-2466/8/6
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In addition to expressing the quantitative results per ml of
lavage fluid, we also expressed all results per mg of lavage
protein. Equal results to those mentioned above were
obtained.
Discussion
Here we present the results of the first systematic compar-
ison of the molecular organisation and concentration of
SP-B or SP-C and their pro-forms in BALF in children with
cystic fibrosis, chronic bronchitis and pneumonia in com-
parison to controls. SP-B was detected regularly at molec-
ular weights of 8 kDa in monomeric respectively 16–18
kDa in dimeric form, additional partly at approximately
30 kDa under non reducing conditions, suggesting the
presence of oligomers in smaller amounts. SP-C was
mainly detected at molecular weights of approximately
4.2 kDa. Some western blots also showed a band at
approximately 7 kDa, which could either be caused by SP-
C-dimers or covalent bonds between SP-C and other thi-
oles [27,28]. Pro-SP-B was found in 60 of 64 samples and
was therefore commonly abundant in all groups, which
corresponds to previous results [10]. Pro-SP-C was not
detected apart from two lavages of CF patients with very
high neutrophil count. No major qualitative or quantita-
tive differences were found between the four groups of
children evaluated, suggesting that both chronic (cystic
fibrosis, chronic bronchitis) and acute (pneumonia) neu-
trophilic inflammation is not associated with pronounced
regulatory changes in these hydrophobic surfactant pro-
teins.
Association of SP-B and SP-C determined under non-reducing conditions with the absolute number of neutrophils (left figures)  and the percentage of neutrophil granulocytes in BALF (right figures) Figure 2
Association of SP-B and SP-C determined under non-reducing conditions with the absolute number of neu-
trophils (left figures) and the percentage of neutrophil granulocytes in BALF (right figures). (  bronchitis,   
pneumonia,   CF,   controls).
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This result is surprising, especially for SP-C, as recently in
various animal models of lung injury the regulation of SP-
C expression by inflammation has been highlighted [1].
Although we found no evidence for down-regulation of
SP-C expression by pulmonary infection and inflamma-
tion, SP-C was not detected in the samples of three
patients with very high percentages of neutrophile granu-
locytes in their lavages. However lower molecular weight
pro-SP-C reactive fragments were detected, suggesting
proteolysis. This was confirmed by re-lavages at later time
points, where less neutrophilic inflammation and normal
SP-C were found. As for SP-B, the quantitative analysis of
SP-C under non reducing conditions did not show a cor-
relation between the level of neutrophilic inflammation
and the amounts of SP-C in the analysed lavage samples.
These data suggest loss of SP-C by proteolysis with severe
inflammation, but not down-regulation from inflamma-
tion.
Comparison of (a) SP-B and (b) SP-C determined under non-reducing conditions between lavage samples positive or negative  for the culture of bacteria Figure 3
Comparison of (a) SP-B and (b) SP-C determined under non-reducing conditions between lavage samples pos-
itive or negative for the culture of bacteria.
Quantitative comparison of SP-B and SP-C, expressed per ml BAL fluid and obtained from analysis of Western blots of SP-B  and SP-C under non-reducing and in the case of controls also und reducing conditions Figure 4
Quantitative comparison of SP-B and SP-C, expressed per ml BAL fluid and obtained from analysis of Western 
blots of SP-B and SP-C under non-reducing and in the case of controls also und reducing conditions. By Kruskal 
Wallis Anova no significant differences were found between the four groups of subjects. Horizontal bar indicates median.BMC Pulmonary Medicine 2008, 8:6 http://www.biomedcentral.com/1471-2466/8/6
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In adults, SP-C content in large aggregate surfactant
remained unchanged in pneumocystis pneumonia, but
decreased significantly in ARDS and other pneumonia
[16]. This may have also been due to proteolytic cleavage;
however proteolytic activity and cleavage products were
not investigated in that study. Previous results in children
with malignancies and immunosuppression during fever
and pulmonary infiltrates [24], and subjects with cystic
fibrosis [13,14] indicated relatively small increases of SP-
C levels, contradicting the view of inflammation induced
down-regulation. Thus the result of the present cross sec-
tional study over a broad range of acute and chronic neu-
trophilc inflammation clearly excludes the hypothesized
changes. However in all these patients, changes with time
and a dependency on the state of infection or inflamma-
tion might be possible and needs to be assessed, similar as
has been done in many of the animal models [1].
Another issue concerns the distribution of SP-B and SP-C
in the alveolar surfactant. Due to shortage of material the
lavages were not separated into large surfactant aggregates
and small surfactant aggregates. However from previous
measurements we know that SP-C is mainly associated
with the large aggregates, whereas SP-B is also present in
the small aggregates, even to a larger extent as might be
anticipated (Griese et al, unpublished). We did also not
perform surface tension measurements of the surfactant
in the lavages. From previous studies it is known that the
impairment in biophysical activity associated with airway
inflammation was not associated with the concentrations
of SP-B and SP-C [14].
Conclusion
Apart from the loss of SP-C in the samples of three
patients with very high amounts of neutrophile granulo-
cytes in their lavages, which was probably due to proteol-
ysis, no significant correlation could be observed between
the level of neutrophilic inflammation and the amounts
of SP-B and SP-C in the lavage samples. In conclusion our
data do not support, if not contradict, the notion of down-
regulation of SP-B and SP-C during acute and chronic
bronchial infection and inflammation in the investigated
human lung diseases.
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